India's benchmarks muted as pharma offsets Mahindra's gains
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 06 2025
0mins
Should l Buy ?
Source: Reuters
Market Performance: India's benchmark indexes opened slightly lower, with the Nifty 50 and BSE Sensex both down by 0.05%, influenced by a decline in pharmaceutical stocks due to U.S. manufacturing incentives, despite gains in the auto sector led by Mahindra & Mahindra.
Sector Highlights: The auto index rose by 1% driven by positive broker outlooks on Mahindra & Mahindra, while the pharma index fell by 1.8% following an executive order from President Trump aimed at boosting domestic drug manufacturing; Ather Energy's IPO was also fully subscribed ahead of its trading debut.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
